Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 7:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Neoadjuvant chemoradiation Clear all
Terminated Phase 1 Interventional Results available

A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT00787852
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47, Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
Drug
Lead sponsor
Brown University
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Sep 23, 2026, 7:43 AM EDT
Active, not recruiting Phase 2 Interventional

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

NCT02451982
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX pancreatic cancer, Nivolumab, Urelumab, BMS-986253
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 23, 2026, 7:43 AM EDT
Active, not recruiting Not applicable Interventional

Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer

NCT04452357
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PLDR
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 23, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma

NCT00682786
View directory record Official record
Conditions
Rectal Carcinoma
Interventions
5FU, Radiation, Surgery of resectable lesions, Irinotecan
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 23, 2026, 7:43 AM EDT
Active, not recruiting Phase 2 Interventional

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT01154920
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Paclitaxel, Carboplatin, Cetuximab, Docetaxel, Cisplatin, Fluorouracil, Radiotherapy (RT), Chemotherapy
Drug · Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 23, 2026, 7:43 AM EDT
Terminated Phase 2 Interventional Results available

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

NCT01133678
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Everolimus, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 23, 2026, 7:43 AM EDT
Active, not recruiting Phase 2 Interventional

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

NCT02688712
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
LY2157299, Capecitabine, Fluorouracil, Tumor specific mesorectal excision
Drug · Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 7:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

NCT02180867
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
365
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 23, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients

NCT00338039
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cetuximab, Gemcitabine, Oxaliplatin, Capecitabine, Radiotherapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 23, 2026, 7:43 AM EDT
Active, not recruiting Phase 2 Interventional

Induction FLOT With CROSS CRT for Esophageal Cancer

NCT04028167
View directory record Official record
Conditions
Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Interventions
Sequential FLOT followed by chemoradiation
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 23, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

NCT00069953
View directory record Official record
Conditions
Esophageal Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
97
States / cities
Burbank, California • Hayward, California • Mission Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 23, 2026, 7:43 AM EDT
Active, not recruiting Phase 1 Interventional

Cryotherapy for Locally Advanced Esophageal Cancer

NCT04248582
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Cryotherapy
Device
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 7:43 AM EDT
Recruiting Phase 2 Interventional

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

NCT04682158
View directory record Official record
Conditions
Esophageal Adenocarcinoma
Interventions
Carboplatin, 3 Dimensional Conformal Radiation Therapy, Propranolol, Intensity Modulated Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 23, 2026, 7:43 AM EDT
Completed Early Phase 1 Interventional

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

NCT01821612
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 23, 2026, 7:43 AM EDT
Terminated Phase 1 Interventional

Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery

NCT01739439
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
gemcitabine hydrochloride, hyperfractionated radiation therapy, intensity-modulated radiation therapy, radiosurgery, diffusion-weighted magnetic resonance imaging
Drug · Radiation · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 23, 2026, 7:43 AM EDT
Recruiting Phase 2 Interventional

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT07489066
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
Interventions
PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
11
States / cities
Huntsville, Alabama • Stanford, California • Athens, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 7:43 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

NCT04018872
View directory record Official record
Conditions
Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Itraconazole
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 7:43 AM EDT
Terminated Not applicable Interventional Results available

Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer

NCT02716896
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
Radiation and chemoradiation, Radical cystectomy
Radiation · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 23, 2026, 7:43 AM EDT
Completed Phase 2 Interventional

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00002774
View directory record Official record
Conditions
Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
Interventions
Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
17 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 23, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer

NCT00114231
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
67
States / cities
Scottsdale, Arizona • Concord, California • Duarte, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 23, 2026, 7:43 AM EDT
Terminated Phase 2 Interventional Results available

Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity

NCT01525927
View directory record Official record
Conditions
Oropharyngeal Neoplasms
Interventions
chemotherapy, radiotherapy, Reduced dose radiotherapy
Drug · Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 23, 2026, 7:43 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer

NCT00603408
View directory record Official record
Conditions
Breast Cancer
Interventions
Cisplatin, Radiation Therapy, Mastectomy
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 23, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Head & Neck Cancer With Chemotherapy and Radiation

NCT00392704
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Bevacizumab, Erlotinib, Paclitaxel, 5-FU, Radiation Therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
7
States / cities
Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Sep 23, 2026, 7:43 AM EDT
Recruiting Early Phase 1 Interventional

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

NCT06831526
View directory record Official record
Conditions
Glioblastoma
Interventions
Azeliragon, Temozolomide, Radiation therapy, Surgery or LITT
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 23, 2026, 7:43 AM EDT